



SmartPA Criteria Proposal

Drug/Drug Class:	Beta Adrenergic Blockers and Beta Adrenergic Blockers/Diuretic Combinations PDL Edit
First Implementation Date:	July 19, 2004
Proposed Date:	September 17, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why was this Issue Selected: Beta-adrenergic blockers inhibit the chronotropic, inotropic and vasodilator responses to adrenaline by blocking β_1 and β_2 receptor sites throughout the body. Several characteristics of beta-blockers may be related to their clinical effectiveness. Beta blockers can be classified by cardioselectivity and intrinsic sympathomimetic activity (ISA). Cardioselective beta-blockers preferentially inhibit only β_1 receptors that are principally found in the myocardium. Non-cardioselective beta blockers inhibit both β_1 and β_2 receptor sites.

Total program savings for the PDL classes will be regularly reviewed.

Program-specific information:

	Non-Preferred Agents
<ul style="list-style-type: none"> • Acebutolol • Atenolol • Atenolol/Chlorthalidone • Bisoprolol • Bisoprolol/HCTZ • Carvedilol • Hemangeol® • Labetalol • Metoprolol Succinate • Metoprolol Tartrate • Metoprolol/HCTZ • Nadolol • Propranolol HCl • Propranolol Soln • Propranolol/HCTZ • Sorine® • Sotalol • Sotalol AF 	<ul style="list-style-type: none"> • Betapace AF® • Betapace® • Betaxolol • Bystolic® • Carvedilol ER • Coreg CR® • Coreg® • Corgard® • Dutorpol® • Inderal LA® • Inderal XL® • InnoPran XL® • Kaspargo® Sprinkle Caps • Lopressor HCT® • Lopressor® • Metoprolol ER/HCTZ • Nadolol/Bendroflumethiazide • Pindolol • Propranolol LA/ER • Sotylize® • Tenoretic® • Tenormin® • Timolol Maleate • Toprol XL® • Ziac®

Type of Criteria:

- Increased risk of ADE
 Appropriate Indications

- Preferred Drug List
 Clinical Edit

Data Sources:

- Only Administrative Databases

- Databases + Prescriber-Supplied

Setting & Population

- Drug/drug class for review: Beta Adrenergic Blockers and Beta Adrenergic Blockers Diuretic Combinations
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents
- For Coreg CE:
 - Documented diagnosis of heart failure **AND**
 - Adequate therapeutic trial on carvedilol twice daily for 30 days
- For Bystolic: Adequate therapeutic trial on one vasodilating alpha/beta-adrenergic blocking agent (labetalol or carvedilol)
- For Hemangeol:
 - Participants aged 2 years and younger **AND**
 - Documented diagnosis of infantile hemangioma **AND**

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- o Maximum treatment length of 6 months; clinical consultant review required to extended treatment
- **For Sotylize and Kapsargo Sprinkle: Clinical Consultant Review for participants aged 10 years or older**

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List Edit)
Rule Type: PDL

Default Approval Period

1 year

References

1. Drug Effectiveness Review Project – Drug Class Review on Beta Adrenergic Blockers. Center for Evidence-Based Policy, Oregon Health & Science University; July 2009; Updated Evidence Scan February 2015.
2. Evidence-Based Medicine and Fiscal Analysis: "Beta Adrenergic Blockers and Diuretic Combination Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2020.
3. Evidence-Based Medicine Analysis: "Oral Beta Blockers (and any beta-blocker combinations)", UMKC-DIC; November 2003 – August 2020.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
5. USPDI, Micromedex; 2020.
6. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.